• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Prenetics Global Limited

    5/7/25 8:47:19 AM ET
    $PRE
    Blank Checks
    Finance
    Get the next $PRE alert in real time by email
    S-8 1 forms-8.htm S-8 Document

    As filed with the Securities and Exchange Commission on May 7, 2025

    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ____________________

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    __________________

    Prenetics Global Limited
    (Exact name of registrant as specified in its charter)

    __________________
    Cayman Islands
    (State or other jurisdiction of
    incorporation or organization)
    Not Applicable
    (I.R.S. Employer
    Identification Number)
    11401 Granite St.
    Charlotte, NC 28273
    USA
    Unit 703-706, K11 Atelier
    728 King’s Road, Quarry Bay
    Hong Kong
    (Address of Principal Executive Offices)

    2022 Share Incentive Plan
    (Full title of the plan)

    Cogency Global Inc.
    122 East 42nd Street, 18th Floor
    New York, NY 10168
    +1 800-221-0102
    (Name, address, and telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer o
    Accelerated filer o
    Non-accelerated filer x
    Smaller reporting company o
    Emerging growth company x
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o



    Copies to:

    Stephen Lo, Chief Financial Officer
    Unit 703-706, K11 Atelier King’s Road 728 King’s Road, Quarry Bay
    Hong Kong
    +852 2210-9588


    EXPLANATORY NOTE

    This registration statement on Form S-8 is being filed by Prenetics Global Limited (the “Registrant”) with the U.S. Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 487,601 shares of the Registrant’s common stock, par value $0.0015 per share (the “Ordinary Shares”) to be issued pursuant to the evergreen provisions (as defined below) of the Registrant’s 2022 Share Incentive Plan (the “Plan”) and to be added to the award pool of the Plan. Pursuant to Section 3.1(a) of the Plan (hereinafter referred to as the “evergreen provisions”), the maximum aggregate number of Ordinary Shares with respect to which awards may be granted under the Plan shall initially be 16,479,399, which will be increased on the first day of each calendar year beginning in 2023, in accordance with a formula set forth in the Plan. This registration statement relates to securities of the same class as those for which the registration statements on Form S-8 (File No. 333-267956, File No. 333-271552 and File No. 333-279019) were filed with the Commission on October 10, 2022, May 1, 2023 and May 1, 2024, respectively (the “Prior Registration Statements”). Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated by reference herein.



    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference

    The following documents filed by the Registrant with the Commission are hereby incorporated into this Registration Statement by reference (other than information in such filings deemed, under Commission rules or otherwise, not to have been filed with the Commission

    a.The Registrant’s Annual Report on Form 20-F (File No. 001-41401) for the year ended December 31, 2024 filed with the Commission on April 30, 2025;

    b.the description of the Registrant’s ordinary shares as contained in its registration statement on Form 8-A (File No. 001-41401), filed with the Commission under Section 12(b) of the Exchange Act on May 17, 2022, including any amendments or reports filed for the purpose of updating such description.

    c.    The Registrant’s registration statement on Form S-8 (File No. 333-267956), filed with the Commission on October 10, 2022;

    d.    The Registrant’s registration statement on Form S-8 (File No. 333-271552), filed with the Commission on May 1, 2023;

    e.    The Registrant’s registration statement on Form S-8 (File No. 333-279019), filed with the Commission on May 1, 2024;

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of this registration statement and prior to the filing of a post-effective amendment to this registration statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents.




    Any statement in a document incorporated or deemed to be incorporated by reference in this registration statement will be deemed to be modified or superseded to the extent that a statement contained in this registration statement or in any other subsequently filed document which also is or is deemed to be incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.





    Item 8. Exhibits

    The Exhibits listed on the accompanying Exhibit Index are filed as a part of, or incorporated by reference into, this registration statement.


    EXHIBIT INDEX

    Exhibit NumberDescription
    4.1
    Amended and Restated Memorandum and Articles of Association of Prenetics Global Limited (incorporated by reference to Exhibit 3.1 to the Form F-3/A (Reg. No. 333-276538), filed with the SEC on February 5, 2024).
    4.2
    Registrant’s Specimen Certificate for Class A ordinary shares (incorporated herein by reference to Exhibit 4.1 of Amendment No. 3 to the Registration Statement on Form F-4 (Registration No. 333-260928) filed with the Securities and Exchange Commission on December 30, 2021, as amended)
    5.1*
    Opinion of Mourant Ozannes as to validity of the Class A ordinary shares being registered
    10.1
    Prenetics Global Limited 2022 Share Incentive Plan (incorporated herein by reference to Exhibit 4.4 of the Shell Company Report on Form 20-F filed with the Securities and Exchange Commission on May 27, 2022)
    23.1*
    Consent of KPMG
    23.2*
    Consent of Deloitte Touche Tohmatsu
    23.3*Consent of Mourant Ozannes (included in Exhibit 5.1)
    24.1*Powers of Attorney (included on signature page hereto)
    107*
    Filing Fee Table
    _________________________
    * Filed herewith.





    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Hong Kong, on May 7, 2025.

    Prenetics Global Limited

    By: /s/ Danny Sheng Wu Yeung
    Name: Danny Sheng Wu Yeung
    Title: Chief Executive Officer




    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned constitutes and appoints each of Danny Sheng Wu Yeung and Lo Hoi Chun, each acting alone, as his or her true and lawful attorney-in-fact and agents, with the power of substitution and re-substitution, for and in such person’s name, place and stead, in any and all capacities, to sign this Registration Statement on Form S-8, or other appropriate form, and all amendments thereto, including post-effective amendments, of Prenetics Global Limited, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each said attorney-in-fact may and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
    SignatureTitleDate
    /s/ Danny Sheng Wu Yeung

    Chief Executive Officer and Chairman of the Board of Directors
    (Principal Executive Officer)
    April 30, 2025
    Danny Sheng Wu Yeung
    /s/ Lo Hoi Chun

    Chief Financial Officer
    (Principal Financial and Accounting Officer)
    April 30, 2025
    Lo Hoi Chun
    /s/ Cheng Yin Pan
    Independent Director
    April 30, 2025
    Cheng Yin Pan
    /s/ David Vanderveen
    Director
    April 30, 2025
    David Vanderveen
    /s/ Kathryn Henry
    Independent Director
    April 30, 2025
    Kathryn Henry
    /s/ Chiu Wing Kwan Winnie
    Independent Director
    April 30, 2025
    Chiu Wing Kwan Winnie






    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

    Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Prenetics Global Limited has signed this registration statement or amendment thereto in the City of New York, New York on May 7, 2025.

    Cogency Global Inc.


    By:     /s/ Colleen A. De Vries
    Name:     Colleen A. De Vries
    Title:     Senior Vice President

    Get the next $PRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRE

    DatePrice TargetRatingAnalyst
    1/18/2023$7.00Overweight
    Cantor Fitzgerald
    7/12/2022Buy
    Citigroup
    More analyst ratings

    $PRE
    SEC Filings

    See more
    • SEC Form S-8 filed by Prenetics Global Limited

      S-8 - Prenetics Global Ltd (0001876431) (Filer)

      5/7/25 8:47:19 AM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form 20-F filed by Prenetics Global Limited

      20-F - Prenetics Global Ltd (0001876431) (Filer)

      4/30/25 4:44:18 PM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form 6-K filed by Prenetics Global Limited

      6-K - Prenetics Global Ltd (0001876431) (Filer)

      3/5/25 8:34:06 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

      LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

      7/1/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

      (From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency) Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in spaceDr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory BoardInaugural research cube scheduled to be sent on-board SpaceX to the ISS in Q4 of 2024 DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Li

      2/9/24 9:25:22 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $PRE
    Financials

    Live finance-specific insights

    See more
    • IM8 Vibrante Miami: Fueling Wellness and Innovation with a Star-Studded Event

      David Beckham was Joined by Dr. Amy Shah, Dr. Jeremy London, Dr. James DiNicolantonio and Kendal Toole to Reinforce IM8's Vision for Elite Wellness Accessible to All CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- On Monday, IM8, the premium supplement brand co-founded by David Beckham, hosted IM8 Vibrante - A Celebration of Science, Wellness & Flavor, a memorable evening at the iconic Faena Theater on Miami Beach. In attendance were nearly 150 wellness influencers, creators, science and medical advisors, and media members to celebrate the brand's ongoing commitment to transforming the status quo of wellness by blending innovation in science and medicine while prioritizing holistic he

      4/9/25 9:00:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics' IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market

      Adds Renowned Clinical Experts Dr. Jeremy London and Dr. Amy Shah to Existing Team from Mayo Clinic, Cedars-Sinai, NASA and Yale University CHARLOTTE, N.C., March 18, 2025 (GLOBE NEWSWIRE) --  IM8, the premium supplements brand co-founded by David Beckham, today announced the addition of two distinguished new members, Dr. Jeremy London and Dr. Amy Shah, to its world-class Scientific Advisory Board (SAB). These additions underscore IM8's unwavering commitment to leading innovation in science, longevity and human performance. Newly joining IM8's SAB are: Dr. Amy Shah – An acclaimed integrative medicine physician and double board-certified expert in Internal Medicine, Dr. Shah focuses on g

      3/18/25 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics to Participate in the 37th Annual ROTH Conference

      CHARLOTTE, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading consumer health sciences company, announced today the Company will participate in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA. Prenetics' Chief Executive Officer Danny Yeung and President of Americas David Vanderveen will be available to host one-on-one meetings with investors during the event. In addition, management will participate in a panel discussion on Longevity and Supplementation on Monday, March 17th at 12:00pm PT. Interested parties may access the panel through the webcast link here w

      3/11/25 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Cantor Fitzgerald initiated coverage on Prenetics Group Ltd. with a new price target

      Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

      1/18/23 7:56:45 AM ET
      $PRE
      Blank Checks
      Finance
    • Citigroup initiated coverage on Prenetics Group Ltd.

      Citigroup initiated coverage of Prenetics Group Ltd. with a rating of Buy

      7/12/22 11:48:35 AM ET
      $PRE
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Prenetics Global Limited

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      11/14/24 12:30:15 PM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      2/5/24 6:05:14 AM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      11/27/23 6:05:43 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces Third Quarter 2024 Financial Results

      Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the third quarter ended September 30, 2024, along with recent business updates. Third Quarter 2024 Financial Highlights Revenue from continuing operations of $7.8 million, as compared to $4.9 million in the thi

      11/27/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces Second Quarter 2024 Financial Results

      Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New Health and Wellness BrandRe-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2024, along with recent business updates. Second Quarter 2024 Financial Highlights Revenue from continuing operations of US$5.9 million, as compared to US$6.5 million in the second quarter 2023 attributable to clinical segment revenues, which are anticipa

      10/7/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry

      Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics' New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, is pleased to announce the acquisition of Europa Sports Partners ("Europa") and subsidiary, Hubmatrix, a global ecommerce and retail logistics provider. This strategic acquisition marks a significant milestone in Prenetics' expansion into the $1

      8/19/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance